Coherus BioSciences logo
Coherus BioSciences CHRS
$ 0.37 -5.13%
report update icon

Quarterly report 2026-Q3
added 11-09-2026

Coherus BioSciences Book Value | CHRS

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.
What is included in book value
  • Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
  • Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
Features of the metric
  • Assessment of the company's "real" value
    Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
  • Comparison with market capitalization
    Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
  • Indicator of financial stability
    If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
  • Key component for financial ratios
    Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Coherus BioSciences

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
61 M -132 M -193 M -137 M 97.7 M 281 M 105 M -38.6 M 30.5 M 19.4 M -6.93 M 66.8 M -42.4 M 9.19 M -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
281 M -193 M 8.57 M

Quarterly Book Value Coherus BioSciences

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
25.2 M 60.8 M 78.6 M 61 M 87.8 M 120 M -183 M -132 M -88 M -84.1 M -81.8 M -193 M -134 M -175 M -197 M -137 M -97.1 M -22.6 M 12.6 M 97.7 M 131 M 156 M 128 M 281 M 256 M 213 M 157 M 105 M 56 M -3.98 M -38.5 M -38.6 M 12.4 M 61.8 M -3.09 M 30.5 M 54.9 M 30.9 M 77 M 19.4 M 31.7 M -61.9 M -66.9 M -6.93 M 40 M 96.4 M 38 M 66.8 M 9.18 M 66.8 M 66.8 M -42.4 M -42.4 M - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
281 M -197 M 17 M

Book Value of other stocks in the Biotechnology industry

Issuer Book Value Price % 24h Market Cap Country
Shattuck Labs Shattuck Labs
STTK
82.4 M $ 4.49 -1.43 % $ 312 M usaUSA
Silence Therapeutics plc Silence Therapeutics plc
SLN
9.06 M $ 19.81 0.08 % $ 2.81 B britainBritain
Soligenix Soligenix
SNGX
5.29 M $ 0.22 -8.25 % $ 1.14 M usaUSA
Sanofi Sanofi
SNY
127 B $ 46.51 0.97 % $ 56.8 B franceFrance
Spruce Biosciences Spruce Biosciences
SPRB
42.5 M $ 38.02 -6.11 % $ 29.1 M usaUSA
Spero Therapeutics Spero Therapeutics
SPRO
59 M $ 0.74 -10.95 % $ 41.5 M usaUSA
Sarepta Therapeutics Sarepta Therapeutics
SRPT
1.14 B $ 13.34 -5.86 % $ 1.34 B usaUSA
Savara Savara
SVRA
203 M $ 4.28 -17.95 % $ 952 M usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
5.17 B - -13.85 % $ 16.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
424 M - - $ 2.91 B usaUSA
Sutro Biopharma Sutro Biopharma
STRO
-132 M $ 8.6 -1.38 % $ 73.1 M usaUSA
Tarsus Pharmaceuticals Tarsus Pharmaceuticals
TARS
343 M $ 72.94 -6.09 % $ 3.05 B usaUSA
Supernus Pharmaceuticals Supernus Pharmaceuticals
SUPN
1.06 B $ 36.28 1.88 % $ 2.05 B usaUSA
TG Therapeutics TG Therapeutics
TGTX
648 M $ 63.39 -2.3 % $ 9.15 B usaUSA
Aphria Inc. Aphria Inc.
APHA
6.38 B - -0.45 % $ 4.87 B canadaCanada
Viridian Therapeutics Viridian Therapeutics
VRDN
722 M $ 29.91 -4.87 % $ 3.05 B usaUSA
Trevi Therapeutics Trevi Therapeutics
TRVI
183 M $ 13.35 -2.73 % $ 1.8 B usaUSA
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.
ARPO
371 M - -0.90 % $ 104 M usaUSA
Chiasma, Inc. Chiasma, Inc.
CHMA
3.57 B - -6.00 % $ 238 M usaUSA
vTv Therapeutics vTv Therapeutics
VTVT
64.4 M $ 16.0 -2.2 % $ 64.2 M usaUSA
Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals, Inc.
ADMS
25.9 M - - $ 376 M usaUSA
Cellect Biotechnology Ltd. Cellect Biotechnology Ltd.
APOP
1.02 B - 0.38 % $ 12.9 M israelIsrael
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
582 M $ 36.89 -1.78 % $ 2.92 B canadaCanada
Xeris Pharmaceuticals Xeris Pharmaceuticals
XERS
13.7 M $ 16.95 2.02 % $ 2.72 B usaUSA
AzurRx BioPharma, Inc. AzurRx BioPharma, Inc.
AZRX
27.2 B - 2.07 % $ 34.4 M usaUSA
X4 Pharmaceuticals X4 Pharmaceuticals
XFOR
186 M $ 3.01 1.69 % $ 127 M usaUSA
Cerecor Inc. Cerecor Inc.
CERC
1.53 B - -1.68 % $ 283 M usaUSA
Constellation Pharmaceuticals, Inc. Constellation Pharmaceuticals, Inc.
CNST
6.62 M - - $ 1.63 B usaUSA
Auris Medical Holding Ltd. Auris Medical Holding Ltd.
EARS
154 M - -1.77 % $ 39.2 M bermudaBermuda
Dicerna Pharmaceuticals, Inc. Dicerna Pharmaceuticals, Inc.
DRNA
101 M - 0.34 % $ 2.98 B usaUSA
ERYTECH Pharma S.A. ERYTECH Pharma S.A.
ERYP
45.8 M - 1.3 % $ 27.7 M franceFrance
GW Pharmaceuticals plc GW Pharmaceuticals plc
GWPH
23 M - - $ 6.81 B britainBritain
22nd Century Group 22nd Century Group
XXII
18.5 M $ 0.32 -19.83 % $ 58.9 K usaUSA
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
8.24 B - - $ 1.7 B usaUSA
Liminal BioSciences Liminal BioSciences
LMNL
36.2 M - - $ 256 M canadaCanada
argenx SE argenx SE
ARGX
7.32 B $ 926.42 -1.66 % $ 56.8 B niderlandNiderland
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp.
TNXP
245 M $ 2.33 -7.25 % $ 19.8 M usaUSA
Zai Lab Limited Zai Lab Limited
ZLAB
716 M $ 21.01 -4.16 % $ 23 B chinaChina
Neos Therapeutics, Inc. Neos Therapeutics, Inc.
NEOS
19.8 M - -2.54 % $ 57.2 M usaUSA
Zentalis Pharmaceuticals Zentalis Pharmaceuticals
ZNTL
216 M $ 1.37 0.74 % $ 98.5 M usaUSA
Zoetis Zoetis
ZTS
3.33 B $ 78.81 -2.47 % $ 34.9 B usaUSA
Odonate Therapeutics, Inc. Odonate Therapeutics, Inc.
ODT
1.44 B - -3.18 % $ 58.5 M usaUSA
Orphazyme A/S Orphazyme A/S
ORPH
148 M - -2.25 % $ 31.3 M danmarkDanmark
Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc
OSMT
6.72 B - -10.74 % $ 89.9 M usaUSA
Pandion Therapeutics, Inc. Pandion Therapeutics, Inc.
PAND
1.77 B - - $ 1.77 B usaUSA
Xenetic Biosciences Xenetic Biosciences
XBIO
7.4 M $ 1.47 -4.55 % $ 2.5 M usaUSA
Translate Bio, Inc. Translate Bio, Inc.
TBIO
493 M - - $ 2.81 B usaUSA
Trillium Therapeutics Inc. Trillium Therapeutics Inc.
TRIL
-2.22 M - - $ 1.94 B canadaCanada
Urovant Sciences Ltd. Urovant Sciences Ltd.
UROV
5.99 B - - $ 532 M britainBritain
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
362 M - - $ 10.9 B usaUSA